Vanguard Capital Management
PCRX icon

Vanguard Capital Management’s Pacira BioSciences PCRX Stock Holding History

Vanguard Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.9M Sell
1,691,571
-92,478
-5% -$2.19M ﹤0.01% 2030
2026
Q1 		$40.3M Buy
+1,784,049
New +$39.6M ﹤0.01% 1973

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's PCRX Position: Q2 2026 in Review

Vanguard Capital Management reduced its Pacira BioSciences (PCRX) stake by 5.2% in Q2 2026, selling an estimated $2.19M and leaving 1,691,571 shares worth $42.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Vanguard Capital Management first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Vanguard Capital Management held 1,691,571 shares of Pacira BioSciences worth $42.9M as of Q2 2026.
  • Vanguard Capital Management sold 92,478 Pacira BioSciences shares in Q2 2026, an estimated $2.19M.
  • Pacira BioSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2030 holding.
  • Vanguard Capital Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 252 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.